Arix Bioscience plc Interim Results for the Six Months Ended 30 June 2018

30th July 2018

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014

Arix Bioscience plc

Interim Results for the Six Months Ended 30 June 2018

LONDON, 30 July, 2018: Arix Bioscience plc (“Arix”, LSE: ARIX) a global healthcare and life science company supporting medical innovation, today announces its interim results for the period ended 30 June 2018.

Financial highlights

£14.4m of investments made into existing portfolio in the period and a further £4.2m in July 2018

Gross portfolio value increased by 71% to £121.8m

Net Asset Value of £257.6m; an increase of 76%

£29.3m profit before tax in the six month period to 30 June 2018

Operational highlights

Nasdaq listing of two Arix companies during the period

Strategic agreements signed by the Company with new investors Fosun International and Ipsen

Positive clinical development within the Group; 15 clinical trials underway

New strategic agreement signed with Fred Hutchinson Cancer Research Center and Evotec AG; further expanding extensive deal sourcing capabilities

Seed investing activity commenced alongside an Arix academic partner

“It has been another positive six months for Arix, during which we had a number of encouraging developments in our Group Businesses, leading to £35.6 million of net positive revaluations. At the half year we have delivered meaningful growth in net asset value and we are well positioned to deliver further over the full year. We ended the period with a healthy cash balance to support existing and new businesses. As a listed company we are able to provide institutional and retail investors access to a diverse portfolio of high growth life science companies, led by some of the most ambitious and brightest minds in biotech.”

Joe Anderson, CEO of Arix

(1) Core portfolio comprises of 13 companies: Autolus Therapeutics, Artios Pharma, Harpoon Therapeutics, Aura Biosciences, LogicBio, Mitoconix, PreciThera, Iterum Therapeutics, Amplyx, Depixus, Verona Pharma, OptiKira and Atox Bio.

For full Interim Results press release please download here